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It is a common practice for decades to use of sub-therapeutic dose of antibiotics in food-
animal feeds to prevent animals from diseases and to improve production performance in
modern animal husbandry. In the meantime, concerns over the increasing emergence of
antibiotic-resistant bacteria due to the unreasonable use of antibiotics and an appearance
of less novelty antibiotics have prompted efforts to develop so-called alternatives to
antibiotics. Whether or not the alternatives could really replace antibiotics remains a
controversial issue. This review summarizes recent development and perspectives of
alternatives to antibiotics. The mechanism of actions, applications, and prospectives of
the alternatives such as immunity modulating agents, bacteriophages and their lysins,
antimicrobial peptides, pro-, pre-, and synbiotics, plant extracts, inhibitors targeting
pathogenicity (bacterial quorum sensing, bioﬁlm, and virulence), and feeding enzymes
are thoroughly discussed. Lastly, the feasibility of alternatives to antibiotics is deeply
analyzed. It is hard to conclude that the alternativesmight substitute antibiotics in veterinary
medicine in the foreseeable future. At the present time, prudent use of antibiotics and the
establishment of scientiﬁc monitoring systems are the best and fastest way to limit the
adverse effects of the abuse of antibiotics and to ensure the safety of animal-derived food
and environment.
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INTRODUCTION
Since the discovery and application of penicillin in 1940s, antibi-
otics have played unparalleled roles in the prevention, control, and
treatment of infectious diseases for humans and animals. It is also
proved that the use of antibiotics in animal feeds is an impor-
tant way to enhance feed efﬁciency, to promote animal growth,
and to improve the quality of the animal products. Recent stud-
ies showed that the growth-promoting effect of antibiotics was
correlated with the decreased activity of bile salt hydrolase, an
intestinal bacteria-produced enzyme that exerts negative impact
on host fat digestion and utilization (Lin, 2014). Therefore, antibi-
otics are effective tools for ensuring the development of intensive
and large-scale farming industry. However, the unreasonable use
of antibiotics has given rise to a fear of the development of
resistant bacteria (Aarestrup et al., 1998) that may lead to the
transfer of resistant bacteria and its resistant factors from ani-
mals to humans (Stanton, 2013). Non-therapeutic antimicrobial
uses are also linked to the propagation of multidrug resistance
(MDR), including resistance against drugs that were never used
on the farm (Marshall and Levy, 2011). Due to this concern,
Sweden ﬁrstly prohibited the use of some of the antibiotics in
animal feeds in 1986 (Castanon, 2007), and European Union (EU)
member nations banned all antibiotic growth promoters in 2006
according to European Parliament andCouncil Regulation ECNo.
1831/2003.
However, the ban of in-feed use of antibiotics has brought
unintended impacts on animal production industries in EU, such
as the increase of infections in animals and the decrease of animal
production. Meanwhile, the total usage amount of antibiotics in
animals increased because the use of therapeutic antibiotics and
disinfectants was signiﬁcantly increased due to the fact that the
high incidence of diseases occurred resulted from the ban. Unlike
its golden age when a lots of antibiotics were discovered and com-
mercialized, the discovery and development of new antibiotics
dramatically decreased for decades (Stanton, 2013). The antimi-
crobial shortages increased by 283% in 2006∼2010 (Borchardt
and Rolston, 2013). The lack of novel core moiety of antibiotics
potentially compensate for the resistance to existing antibiotics
and owes to the high cost and risk associated with the devel-
opment and application of such products (Cooper and Shlaes,
2011).
To overcome the increased rate of mortality and morbidity
due to the ban of in-feed antibiotics, a number of alterna-
tives/replacements have been proposed (Seal et al., 2013). They
are antibacterial vaccines, immunomodulatory agents, bacterio-
phages and their lysins, antimicrobial peptides (AMPs), pro-,
pre-, and synbiotics, plant extracts, inhibitors for bacterial quo-
rum sensing (QS), bioﬁlm and virulence, and feed enzymes,
etc. (Millet and Maertens, 2011). Are these antibiotic alternatives
really as effective as antibiotics to control the diseases in animals?
www.frontiersin.org May 2014 | Volume 5 | Article 217 | 1
Cheng et al. Antimicrobial alternatives
The development and application of the alternatives to antibiotic
was reviewed, and the possibility of the alternatives to antibiotics
was discussed in this paper.
IMMUNITY MODULATING AGENTS
The development of an infection is the interaction between the
pathogen and the immune system of the host. The immune sys-
tem protects the body against the disease by recognizing and
neutralizing the pathogen. The innate immune response includes
both humoral and cellular defense such as the complement sys-
tem and the processes played by granulocytes and macrophages.
Immunity modulating agents (immunomodulators) are used for
immunotherapy,which is deﬁned as treatment of disease by induc-
ing, enhancing, or suppressing an immune response. Vaccine
is one of the most important immunomodulators, and some
pharmaceutical agents could also be used as immunomodulators.
ANTIBACTERIAL VACCINES
Traditional vaccines are generally classiﬁed into live-attenuated
and inactivated/killed vaccines. Bacterin is a suspension of killed
or weakened bacteria used as a vaccine. Live-attenuated bacteria,
replicating transiently in the host, are capable of expressing a full
repertoire of antigens. Take Salmonella vaccine for an example.
Many live Salmonella vaccine strains have been tested with vary-
ing degrees of efﬁcacies (Desin et al., 2013). However, the major
drawbacks of the live strains is that they persist in the animal
body for a longer time (Tan et al., 1997) and have a high risk of
reverting to full virulence (Barrow, 2007; Gast, 2007). Although
various Salmonella live-attenuated vaccines have been reported,
not all of them have been tested under ﬁeld conditions. In addi-
tion, they do not induce sufﬁcient cross protection against other
non-host-adapted serotypes (Desin et al., 2013).
Killed vaccines are safer than the live vaccines. It is made
by killing in vitro-grown bacterial cultures and packing with
oil-based adjuvants to enhance immune responses (Potter et al.,
2008). They are quite inexpensive in production and stable
in storage. The inactivated autogenous poultry vaccines cur-
rently include Pasteurella multocida, Salmonella, Mycoplasma,
Ornithobacterium, Haemophilus, Staphylococcus, Escherichia coli,
and Bordatella Bacterins. However, killed vaccines have numer-
ous disadvantages such as the lack of relevant protective antigens
(PAs) due to in vitro growth conditions and killing processes
(Barrow, 2007; Gast, 2007), antigenic competition between non-
protective and protective components, a lack of safety due to
potentially harmful components such as lipopolysaccharide, and a
lack of broad-spectrum protection. In addition, killed vaccines
require the use of adjuvants which limits the delivery options
for the vaccines. Moreover, most of the killed vaccines are
injectable products and are not routinely used in intensive broiler
operations.
With the increasing use of bacterins, there are concerns that this
may lead to the increasing virulence of bacteria. As an alternative,
subunit vaccine is composed of either a single antigen or multiple
deﬁned antigens (predominantly proteins). This kind of vaccines
lack the regulatory and biological complications associated with
the living organisms. On the other hand, subunit vaccines are usu-
ally poorly immunogenic, requiring formulation with appropriate
adjuvant(s) (Mutwiri et al., 2011). Although Salmonella subunit
vaccines are under development, it is hard to conclude that one
class of vaccines is more efﬁcacious than another (Desin et al.,
2013). Besides, the use of oral subunit vaccines in large animals
remains problematic due to the degradation of the antigens and
poor absorption in guts (Potter et al., 2008).
DNA vaccines offer another promising improvement to con-
ventional vaccines (Haygreen et al., 2005). DNAvaccine ismadeup
of a small, circular piece of bacterial DNA (called a plasmid) that
has been genetically engineered to include the DNA sequence(s)
encoding the antigen(s) from a pathogen. When the vaccine DNA
is injected into the cells of the body, the host cells “reads” the DNA
and converts it into pathogenic proteins which would trigger a
range of immune responses. Nevertheless, DNA vaccine is limited
in its protective capacity to the encoded proteins on the vector
and may pose a risk of integrating the genetic elements of the
vector into the host genome. Most of the literatures dealing with
DNA vaccines have described the use of viral antigens delivered in
mouse models. However, when they are used in large animals,
results are often disappointing (Potter et al., 2008). Therefore,
DNA vaccines are unlikely to reach the market until the plasmid
dose can be controlled and the problems of effective delivery are
solved.
Unlike the anti-viral vaccine market which is quite mature, the
available antibacterial vaccines are still rare in market. For exam-
ple, no vaccines are commercially available for either C. jejuni
or E. coli O157 although immunization against both of these
strains has been respectively demonstrated in chicken and cat-
tle (Potter et al., 2008). In the case of E. coli O157, immunization
with bacterins has not shown any protection effect. Although vac-
cines against E. coli and Brachyspira hyodysenteriae for treating
swine dysentery have been reported (Francis and Willgohs, 1991;
Song et al., 2009), safety and efﬁcacy data are still lacking, hin-
dering the commercialization process of these biological products
(Ruan et al., 2011). S. aureus vaccines are developed for bovine
mastitis, but a systematic review evaluating 24 in vivo studies sug-
gests that the methodological differences and a lack of more rigid
scientiﬁc criteria (such as double blind protocols) in some cases
hinder the assessment of the efﬁcacy of these vaccines (Pereira
et al., 2011). Moreover, the protection rates of animals by antibac-
terial vaccine in the market are low (Buckley et al., 2010; Crouch
et al., 2010).
Last but not least, the development of a vaccine that is
both practical and inexpensive so that it can be affordable for
use in poor countries is still a key problem (Zhang and Sack,
2012). As for poultry vaccines, the most important challenge for
mass immunization is the cost of vaccine as well as the abil-
ity in most cases. While vaccines may lessen our reliance on
the use of antibiotics, they are complementary rather than a
replacement.
OTHER IMMUNOMODULATORS
Immunomodulators, mainly immunostimulants, are able to non-
speciﬁcally enhance the innate immune function and to improve
the host’s resistance to diseases. The use of immunotherapy
in infectious diseases may resulting in modulating the immune
response to a microbe (e.g., by using cytokines and cytokine
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inhibitors), modifying a speciﬁc antigen-based response (e.g.,
using interferons) and minimizing end-organ damage using non-
speciﬁc anti-inﬂammatory agents (e.g., steroids; Masihi, 2000).
β-Glucans, bacterial products, and plant constituents could
directly initiate activation of innate defense mechanisms acting
on receptors and triggering intracellular gene(s) that may result in
the production of antimicrobial molecules.
There is a variety of immunostimulants, no less than a dozen
categories with hundreds of varieties (Table 1). Since 1990s,
nucleotides, thymosin, and oregano oil have mainly been used
as immunostimulants. Later, probiotics, herbs and their extracts
have also become subjects to immunostimulant studies (Thacker,
2010). Studies in animals exhibit signiﬁcant health beneﬁts by
using β-1,3/1,6-glucan (from yeast cell walls) as a feed ingredi-
ent to protect animals against microorganisms (Williams et al.,
1996). It is suggested that the use of immunostimulants as feed
additives can improve the innate defense of animals, providing
resistance against pathogens during periods of high stress, such
as grading, reproduction, transfer, and vaccination (Bricknell and
Dalmo, 2005).
Many factors affect the efﬁcacy of immunostimulants.
Immunostimulants exhibit different effects in different animal
species. They do not reveal a linear relationship between dose
and effect, usually more efﬁcient during or prior to infec-
tion. Besides the beneﬁcial effects, immunostimulants have so
broad effects among which they inhibit the protective aspects
of the host immune system (Thacker, 2010). When immuno-
genic stimulation persists or autoregulatory immune mechanisms
cease, adaptive immunologic events can result in immune-
mediated processes detrimental to systemic or organ-speciﬁc
homeostasis (Moore, 2004). It has been proposed in larval ﬁsh
aquaculture that the delivery of immunostimulants as a feed
additive could be of considerable beneﬁt in boosting the ani-
mals’ innate defense with little detriment to the developing
of ﬁshes. Conversely, immunomodulating a neotenous ani-
mal before its immune system is fully formed may adversely
affect the development of a normal immune response (Bricknell
and Dalmo, 2005). Importantly, most immunomodulators just
enhance the immune systemof animals, rather thandirectly kill the
bacteria.
Presently, there are no uniform standards for evaluating
the efﬁcacy and safety of immunostimulants. It was reported
that a reputed immunostimulant composed of Propionibacterium
acnes extract,Ochrobactrum intermedium lipopolysaccharides and
Proclin® did not affect the immune system of goats (Morales-
delaNuez et al., 2009). The widespread notion of immunostimu-
latory plant natural products and their potential therapeutic use is
rather obscure, suggesting that the product is some sort of “tonic”
for the immune system without actually specifying the mecha-
nisms (Gertsch et al., 2011). It is argued that the paradigm of oral
plant immunostimulants lacks clinical evidence, originating from
primary in vitro studies. No conclusive data on orally administered
immunostimulants can be found in the scientiﬁc literatures up to
now. Overall, immunotherapy to modulate the immune response
just can be used as an adjunct to the antimicrobial therapy (Kak
et al., 2012).
Table 1 | Classification of immunostimulants.
Category Variety
Mineral substances Selenium, zinc, etc.
Vitamins Vitamin A, vitamin E, vitamin C, etc.
Amino acids Arginine, leucine, ubenimex, etc.
Chinese herbal medicines Astragalus, Echinacea, etc.
Plant polysaccharides Astragalus polysaccharide, lentinan, algal polysaccharides, ganoderan, Polyporus polysaccharide, chitosan,
etc.
Oligosaccharides Mannan-oligosaccharides, fructooligosaccharide, etc.
Microbial preparations BCG vaccine, corynebacterium seedlings, Lactobacillus, cholera toxin B subunit, Mycobacterium phlei,
muroetasin, prodigiosin, etc.
Immunologic adjuvants Aluminum adjuvant, propolis, liposome, Freund’s adjuvant, etc.
Hormones and hormone-like substances Growth hormone, thymosin, metallothionein, thymopentin, etc.
Nucleic acid preparations Polynucleotide, immune ribonucleic acid, etc.
Anthelmintics Levomisole, metronidazole, etc.
Chemical synthetics Levomisole, cimetidine, sodium houttuyfonate, imiquimod, pidotimod, ubenimex, tilorone, polyinosinic acid,
etc.
Bacterial extracts β-Glucan, peptidoglycan, lipopolysaccharide, etc.
Biological (cytokines) Interferon, transfer factor, interleukin, immune globulin, etc.
Others Bee pollen, bursa extracts, gamma globulin, heat shock protein, poly IC, glycyrrhizin, etc.
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BACTERIOPHAGES AND THEIR LYSINS
BACTERIOPHAGES
Bacteriophages are viruses that are parasitic on bacteria, and they
have been considered as one of the types of agents to treat bacte-
rial infections for a long time (Wittebole et al., 2014). They were
ﬁrst discovered by Frederick Twort in UK in 1915 and by Félix
d’Herell in France in 1917. The ﬁrst study on the clinical use
of phage was published in Belgium in 1921 by Bruynoghe and
Maisin who injected staphylococcus-speciﬁc phage near the base
of the cutaneous boils to treat cutaneous furuncles and carbuncles.
The commercial phages was introduced by two companies in the
United States and France in 1940s. Recent animal studies show that
phage therapy is worth of recognition (O’Flaherty et al., 2009). It
is reported that phages has certain preventive effects on pathogens
as E. coli O157:H7, Salmonella and Campylobacter (Huff et al.,
2005; Johnson et al., 2008). In 2006, a phage cocktail desig-
nated LMP-102TM containing six types of pure bacteriophages was
approved by US-FDA as a food additives for prevention of meat
contaminationwith Listeria. In 2007,United States Department of
Agriculture (USDA) approved another phage product to be used
for disinfection of E. coli in hidden parts of cattle. Nonetheless,
most of the bacteriophage products to date are still in the research
stage.
Bacteriophages can replicate in host cells and are able to pro-
duce new lytic phages to keep pacewith themutation of pathogens.
However, the replacement of antibiotics by phages in treatment of
bacterial diseases encounters controversy because of the following
characteristics (Pirnay et al., 2011):
(1) Since phages have strict host strain speciﬁcity, the precise
etiologicalmicroorganismcausing infectionneeds to be deter-
mined with accuracy before the use of phage therapy (Allen
et al., 2013). Also, the narrow host range impedes the abil-
ity of a single kind of phages to be used as replacement of
antibiotics, which are typically broader in their antibacterial
spectrum;
(2) Since they are viruses, phages can be seen by the immune
system of the host as a potential invader and may there-
fore rapidly be eliminated from the systemic circulation by
reticulo-endothelial system clearance before they are accu-
mulated in the target sites, or, they may be inactivated by
the adaptive immune defense mechanisms (Dabrowska et al.,
2005), which may lead to the treatment failure (Merril et al.,
1996);
(3) Another concern of phage therapy is the potential ability of
bacteriophages to transfer their DNA from a bacterial cell
to another. This could be responsible for the transfer of
pathogenicity determinants and virulence factors, leading to
the development of a new microbe or even more resistant
bacteria (Brabban et al., 2005; Maiques et al., 2007). There-
fore, the use of phages that are unable to package extra
host DNA or of phages that use the host DNA to synthe-
size its own DNA would be preferred (Gorski et al., 2009).
In addition, under certain conditions, lytic phages would
be transformed into lysogenic phages, making it possible
to transfer their own virulence factors to the host bacteria
(Brussow, 2007);
(4) Pharmacokinetic characteristics of phages are barely
known. Optimal dose, route of administration, fre-
quency, and duration of treatment still need to be
deﬁned before widespread clinical trials are contem-
plated;
(5) Phage therapy is time-sensitive. Use phages early in a dis-
ease setting could obtain a better therapeutic effect. For
example, when the phages were given immediately after
the infection of E. coli O18ac:K1:H7 ColV+, the efﬁcacy
was 100%; whereas when phage treatment was carried out
16 h after infection, the therapy failed (Smith and Huggins,
1982);
(6) Phages can cause the release of toxins, e.g., endo-
toxin (LPS), in large quantities from bacteria, especially
Gram-negative bacteria. This may account for several
side effects on the host such as the development of an
inﬂammatory cascade leading to a multiple organ fail-
ure;
(7) Bacteria can obtain resistance to phages by mutation.
The mutation rates for antibiotics and phages are 10−7
and 10−6, respectively (Carlton, 1999). There are at
least four mechanisms that may be involved in bacterial
resistance to a speciﬁc phage. Loss or lack of recep-
tor (Liu et al., 2002), structural modiﬁcation (Riede and
Eschbach, 1986) and/or masking of the receptor (Drulis-
Kawa et al., 2012) may prevent phage adsorption to the
bacteria and prevent further an ability to generate new
phages. The other mechanisms include the prevention of
phage DNA integration by superinfection exclusion sys-
tem (Sie), the degradation of phage DNA by restriction–
modiﬁcation defense system or by clustered regularly inter-
spaced short palindromic repeats (CRISPR), and the blockage
of phage replication, transcription, translation, or virion
assembly by abortive infection system (Drulis-Kawa et al.,
2012);
(8) Some phages can only survive in the intestines when
bacteria counts reach certain numbers. Phages can only
reduce but not completely eliminate S. typhimurium in
the animal intestines (Berchieri et al., 1991; Callaway et al.,
2011);
(9) Preparation of phages should be at a low temperature (Bur-
rowes et al., 2011), and this kind of biological products are not
stable.
Currently, the main challenge for the promotion of phage
preparations is the lack of data obtained from large-scale clinical
trials, thus hindering the universal application of them. Regu-
latory loopholes remain another major hurdle. In addition to
the inherent safety concern, neither the US-FDA nor the Euro-
pean Medicines Agency has an approval process in place that can
easily accommodate the ever-changing combinations of phages
that accompanies the need to continuously develop the prod-
uct in order to stay one step ahead of evolving MDR bacteria
(Miedzybrodzki et al., 2012).
ENDOLYSINS
Endolysins, including glucosidase, amidase, endopeptidase, and
transglycosylase, are generated at the late phage lytic cycle,
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degrading bacterial peptidoglycan to facilitate the release of new
phages from the infected bacteria. Endolysins were ﬁrst discov-
ered in the 1950s (Ralston et al., 1955), and revealed antibacterial
activity against Staphylococcus, Bacillus anthracis, L. monocy-
togenes, and Clostridium butyricum in the 1990s (Low et al.,
2005). Endolysins can treat sepsis and a few Gram-positive
bacteria infections, such as Enterococcus faecalis, C. perfrin-
gens, and Group B Streptococcus (Fenton et al., 2010). Endolysin
PAL is able to kill Group A Streptococcus which cause tonsilli-
tis and other infections. Amidase PAL and endopeptidase Cpl-1
from phage Cpl-1 is capable of synergistically reducing the inci-
dence of local and systemic pneumococcal disease (Loefﬂer et al.,
2003; Fischetti, 2005). Endolysins LysK from phage K could
kill nine Staphylococcus, including methicillin-resistant S. aureus
(MRSA; O’Flaherty et al., 2005). Endolysins PlyV12 shows a good
lytic activity against Enterococci, vancomycin-resistant E. faecalis
and E. faecium (Yoong et al., 2004). Endolysins isolated from
phage phi3626 can treat Clostridium infections (Courchesne et al.,
2009).
Endolysins can quickly kill susceptible strains with wider
antibacterial spectrum than phages and the activities are easier
to be detected. Long-term evolution of endolysins makes them
target only for some of the key elements on bacterial cell walls
(Loefﬂer et al., 2003) thus cause bacteria lysed fast. Therefore,
there is not enough time for bacteria to develop a resistance (Fis-
chetti, 2005). However, the conventional methods for endolysin
production are complicated, making the cost higher than that of
the phage production. The use of recombinant DNA technology
can reduce the costs (Loefﬂer et al., 2001), but it cannot guarantee
the correct structure and full activity of the enzymes. Meanwhile,
endolysins are easily degraded and lose activities during use and
storage; hence they should be usedwith a full dose. In addition, the
efﬁcacy of endolysins is poor against Gram-negative bacteria; thus
the use of single type of endolysin limits the scope of application.
Future studies will focus on the chimeric endolysin (O’Flaherty
et al., 2009), which could widen the antibacterial spectrum of this
kind of enzymes. Presently, there are no published clinical studies
concerning the endolysins.
VIRION-ASSOCIATED PEPTIDOGLYCAN HYDROLASES
Bacteriophage virion-associated peptidoglycan hydrolases
(VAPGHs) are a kind of phage lyases that hydrolyze bacterial pep-
tidoglycan to assist the entry of phages into the bacterial cells
(Rodriguez-Rubio et al., 2013). Many VAPGHs have been discov-
ered and proved exhibiting antibacterial activities. Protein HydH5
from phage phiIPLA88 shows higher activity against S. aureus in
the early logarithmic growth phase (Rodriguez et al., 2011). Pro-
tein 17 from phage P68 and protein gp61 from phage phiMR11
exhibit lytic activity against S. aureus including MRSA (Takac
and Blasi, 2005; Rashel et al., 2008). Protein P5 from phage 6
possess the antibacterial activity against Pseudomonas, E. coli, S.
typhimurium, Proteus vulgaris, and other Gram-negative bacteria
whose outer membrane structures are unstable (Caldentey and
Bamford, 1992). Protein Gp181 from phage KZ demonstrates a
lytic activity against the above mentioned Gram-negative bacte-
ria as well as Ralstonia solanacearum and Yersinia. Protein gp36
of phage KMV is effective against P. aeruginosa and E. coli,
and exhibits a high thermal stability as the enzyme retained
26% of activity after incubation at 100◦C for 2 h (Lavigne et al.,
2004).
Currently, the researches onpuriﬁedVAPGHs are limited. Since
bacterial resistance caused by endolysin has not been reported to
date, this may also be the case for VAPGHs (Rodriguez-Rubio
et al., 2013). VAPGHs from Gram-negative bacterial phages have
broad antimicrobial spectrum while the antibacterial spectrum
of VAPGHs from Gram-positive bacterial phages only conﬁne
to speciﬁc host bacteria. VAPGHs are also effective against
some antibiotic-resistant pathogens, increasing their application
prospects (Paul et al., 2001; Rodriguez-Rubio et al., 2012). Many
VAPGHs exhibit thermal stability, retaining activity at high tem-
peratures generally associated with food technology. Taking into
account that extracellular action can reduce the intracellular action
which may trigger widespread bacterial resistance mechanisms,
such as efﬂux pumps, VAPGHs provides an alternative source
for bacterial lyases except for endolysins (Rodriguez-Rubio et al.,
2013).
ANTIMICROBIAL PEPTIDES
Antimicrobial peptides are classiﬁed into two categories, non-
ribosomally synthesizedAMPs and ribosomally synthesizedAMPs,
according to thepeptide synthesismechanism. Thenon-ribosomal
AMPs, mainly produced by bacteria, are synthesized by peptide
synthetases and structural modiﬁcations. They include grami-
cidin, polymyxin, bacitracin, and sugar-peptide. Polymyxin is
fromB. polymyxa, playing bactericidal effect by destroying the bac-
terial cell membranes. It is effective against many Gram-negative
bacteria, such as P. aeruginosa, E. coli, Klebsiella pneumoniae,
Haemophilus, and Salmonella. Bacitracin is a cyclic peptide pro-
duced by B. subtilis and B. licheniformis, and it functions by
inhibiting the synthesis of cell wall peptidoglycans and glycopro-
tein core oligosaccharides in Gram-positive bacteria. Bacitracin
shows bactericidal effects against Gram-positive bacteria, Gram-
negative cocci and spirochetes. The USA and China have approved
the use of bacitracin zinc and bacitracin methylene salicylic acid as
feed additives in 1960 and 1990, respectively. These two bacitracins
have a wide compatibility with other medicines.
Ribosomally synthesizedAMPs can be further classiﬁed accord-
ing to the sources of the peptides, such as mammals, amphibians,
insects, plants, bacteria, viruses, etc. These AMPs are not only
anti-bacterial or anti-mycotic, but also anti-protozoal, anti-
viral, or anti-neoplastic, with broad application prospects. The
positive charges of AMPs could form electrostatic adsorption
with negatively charged phospholipid molecules on the bac-
terial cell membranes, resulting in structural damage of the
membranes.
There are many reports on the protective effect of AMPs on
humans (Guani-Guerra et al., 2010) and animals (Leonard et al.,
2012). Here, bacteriocins which are produced by bacteria are taken
as an example. Bacteriocins are deﬁned into four classes as lantibi-
otics, the small heat-stable peptides (SHSPs), the large heat-labile
proteins (LHLPs), and undeﬁned mixture proteins with lipids and
carbohydrates (Bierbaum and Sahl, 2009). Bacteriocins can also be
subdivided on the basis of their modiﬁcations into class I (modi-
ﬁed) and class II (unmodiﬁedor circular; Cotter et al., 2013). There
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have been lots of identiﬁed bacteriocins such as nisin, lactacin,
lactocin, helveticin, fermenticin, sakacin, lacticin, plantacin, sub-
ticin, etc. In vitro tests show that bacteriocins have strong killing
and suppressive effects on a variety of pathogens, including resis-
tant pathogens (Field et al., 2011). In 1988, nisin received the
US-FDA approval as food additive for the ﬁrst time. Pediocin
PA-1 from Pediococcus is on the market now. However, pure
bacteriocins have so far only few and limited authorized uses in
foods.
Bacteriocins have been found to have many distinct mecha-
nisms of action. In addition to punch holes in the cell membrane
like other AMPs do (Cotter et al., 2005), nisin, several lantibi-
otics and some class II bacteriocins, target lipid II (Bierbaum and
Sahl, 2009), a key intermediate in the peptidoglycan biosynthesis
machinery. Besides, bacteriocins can kill bacterial cells by interfer-
ing with DNA, RNA, and protein metabolism. MccB17 functions
by inhibiting DNA gyrase-mediated DNA supercoiling, thereby
interfering with DNA replication (Parks et al., 2007). MccC7-C51
inhibits aspartyl-tRNA synthetase, thus blocking mRNA synthesis
(Metlitskaya et al., 2006). Nocathiacins and several other thiopep-
tides target the bacterial ribosome, binding the 23S rRNA of the
50S ribosomal subunit (Bagley et al., 2005).
Although AMPs are with good bactericidal effects and eas-
ily digested by bodies without adverse effect to the taste of feed
or polluting the environment, a number of constraints have
accompanied with the deepening research concerning AMPs.
(1) The high production cost limits the use of AMPs as effective
antibiotic alternatives to livestock. Nowadays, bacteriocins are
produced traditionally by culturing the wild strains, but the
yield is low and the puriﬁcation process is complex;
(2) Scientists begin to use genetic engineering techniques to syn-
thesize bacteriocins owing to their peptidenature because they
are directly encoded by genes (Cotter et al., 2013). AMPs can
be modiﬁed by protein engineering to improve their efﬁcacy.
Site-saturation mutagenesis approach is used to create a bank
of nisin A derivatives to screen the ones exhibiting enhanced
bioactivity (Molloy et al., 2013). However, it cannot guarantee
that the spatial structures of AMPs obtained by genetic engi-
neering are consistent with the those of natural AMPs, which
often causes differences in activities (Field et al., 2011);
(3) Many natural AMPs, such as melittin (a peptide which is
the principal active component of bee venom), buthotoxin
(a scorpion venom polypeptide) and plant AMPs, are poten-
tially toxic to eukaryotic cells due to their hemolytic effects.
Recently, a potent E. coli displaying multimeric AMPs on the
cell surface was constructed (Shin et al., 2013). The multi-
meric AMPs can be converted into active AMP monomers by
the pepsin in the stomach of livestock;
(4) Antibacterial spectrum of most bacteriocins is narrow, only
effective to the related bacterial species (Lee and Kim, 2011);
(5) Bacteria can still develop resistance to AMPs by reducing
the corresponding receptors (Piper et al., 2009), changing the
composition of cell wall (Kramer et al., 2006), or changing the
primary target of bacteriocin (del Castillo et al., 2001). Some
bacteria can also utilize immune genes (Draper et al., 2009)
or bacteriocin-hydrolase (Sun et al., 2009; Nocek et al., 2012)
to obtain resistance. In fact, the widely used polymyxin AMPs
has caused serious resistance in clinically important bacterial
species, in both human and veterinary medicine;
(6) In vivo studies about pharmacodynamics, pharmacokinetics,
and stability of AMPs are few. It is unclear whether AMPs or
their metabolites are harmful to the body, and the immune
response and other issues still need to be veriﬁed;
(7) AMPs are unstable during transportation, and are easily
hydrolyzed by proteases in the alimentary canal during use.
PRO-, PRE-, AND SYNBIOTICS
PROBIOTICS
Probiotics have been deﬁned by the World Health Organization
as “microorganisms which, administered live and in adequate
amounts, confer a beneﬁt to the health of the host.” Probiotics
are considered to be able to destroy pathogenic microorganisms
by producing antimicrobial compounds such as bacteriocins and
organic acids, improve gastrointestinal microbial environment by
adherence to intestinal mucosa thereby preventing attachment of
pathogens and competing with pathogens for nutrients, stimu-
late the intestinal immune responses and improve the digestion
and absorption of nutrients. The commonly used probiotics
include Bacillus, Lactobacillus, Lactococcus, Streptococcus, Ente-
rococcus, Pediococcus, Biﬁdobacterium, Bacteroides, Pseudomonas,
yeast,Aspergillus, andTrichoderma, etc. Microbiological feed addi-
tives used in EU mainly include Bacillus (B. cereus var. toyoi,
B. licheniformis, B. subtilis), Enterococcus (E. faecium), Lacto-
bacillus (L. acidophilus, L. casei, L. farciminis, L. plantarum, L.
rhamnosus), Pediococcus (P. acidilactici), Streptococcus (S. infan-
tarius), and some fungi such as Saccharomyces cerevisiae and
kluyveromyces (Anadon et al., 2006). Japan started using probi-
otics in 1960s, and China began the application of probiotics in
1980s. US-FDA approved 42 probiotics till 1989 (Gaggia et al.,
2010). In 2000, the total sale of feed probiotics worldwidewas $186
million.
However, the probiotic market is very less organized and the
supervision and management of probiotic production are defec-
tive. For instance, China Ministry of Agriculture has approved 12
probiotics, but there are more than 50 probiotics being used in
China. Due to lack of standards, animal poisoning, allergies, and
diarrhea after using probiotics are reported from time to time.
Despite years of experiences in the use of lactobacilli and biﬁ-
dobacteria which are proved to be safe, the safety of other species
still need to be examined (Borriello et al., 2003). Meanwhile, probi-
otics are potentially harmful to the congenitally immunodeﬁcient
animals (Balish and Wagner, 1998). Besides, previous studies have
failed to consistently prove the beneﬁcial effects of probiotics in
animals. For example, microcin-producing E. coli could inhibit
the growth of Salmonella in vitro, but the results in vivo were
not satisfactory (Frana et al., 2004). Contradictory results with
very heterogeneous studies are reported on the treatment and the
prophylaxis of upper respiratory tract infections (Alexandre et al.,
2014). Furthermore, probiotics have adverse effect on the nor-
mal gut ﬂora. Lactobacillus and Bacillus can destroy the ecological
balance of normal ﬂora in the body, which may be related to the
occurrence of urinary tract infections and other diseases. Dietary
cider yeast can potentially alter the gut microbiota. However, such
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changes depend on their endogenous microbiota that causes a
divergence in relative response to that given diet (Upadrasta et al.,
2013).
For putting probiotics into practice as feed additives, the fol-
lowings are challenged: (1) the number of safe bacterial species is
limited; (2) microbial preparations are easily inactivated in feed
processing, transport, and storage processes; (3) they cannot with-
stand low pH in gastrointestinal tract and bile acids during use;
(4) it is difﬁcult to reach high enoughnumber of viable cells to col-
onize in the intestine. In addition, because there are no adequate
corresponding regulations and standards, probiotic products can-
not be labeledwith proper dose, indicated in suitable animal target
as well as other factors that may affect the efﬁcacy.
PREBIOTICS
Prebiotics are non-digestible (by the host) food ingredients
that have a beneﬁcial effect through their selective metabolism
in the intestinal tract (Gibson et al., 2004). Prebiotics include
oligosaccharides [such as fructooligosaccharide (FOS), mannan-
oligosaccharide (MOS)], polysaccharides, natural plant extracts,
protein hydrolysates, polyols, etc. Prebiotics can selectively prolif-
erate intestinal bacteria, promote immune functions and show
anti-viral activity. Some of them are able to promote mineral
absorption and regulate metabolism. The applications of prebi-
otics as feed additives began in the late 1980s. China began to use
them in the late 1990s. Currently, the most promising prebiotics
are multifunctional oligosaccharides and acidiﬁers.
Prebiotics are stable compounds with no residue, no induced
resistance, and wide variety of sources. However, nowadays in EU
manyprebiotic products are not authorized as feed additives under
the commission regulation (EC) 1831/2003 (European Commis-
sion,2003). This is due to somedrawbacks of this kind of products.
First, prebiotics themselves cannot inhibit and kill pathogens, thus
they cannot prevent or treat bacterial infections as antibiotics
do. Second, feeding with large quantity of prebiotics may cause
bloating, diarrhea, and other adverse reactions due to the fermen-
tation in the gastrointestinal tract (de Vrese and Schrezenmeir,
2008). Third, a study suggests that the prebiotic role of mannose
is related to its oligosaccharide structure (Badia et al., 2013). Both
β-galactomannan and MOS from yeast Saccharomyces cerevisiae
attenuates Salmonella-induced secretion of IL6 and CXCL8, but
cells treated with monosaccharide D-mannose show similar levels
of these proinﬂammatory factors compared with the control of
infection. Since the relationship between structure and physiolog-
ical function of prebiotics is not clear, the efﬁcacy of prebiotics
is always variable with different animal species, ages, and physical
conditions. Sometimes, mutual antagonism occurs. In addition,
the high cost of prebiotic production limits their application in
the animal husbandry industry.
SYNBIOTICS
Synbiotics are the joint preparations of probiotics and prebi-
otics, and thus have the dual role of them (Andersson et al.,
2001). There are some reports on the effect of synbiotics on the
physiological and biochemical indexes of piglets including the
enhancement of immune function in piglets, the improvement
of average daily gain and digestibility, the reduction of diarrhea
morbidity and mortality, the ease of weaning stress response, and
the signiﬁcant promotion of piglet performance (Gaggia et al.,
2010). However, the reports of the beneﬁcial effects of synbi-
otics on swine production are still limited (Modesto et al., 2009).
The mixing proportions of probiotics/prebiotics for the major-
ity of synbiotics are inadequate (Kolida and Gibson, 2011), thus
resulting in a non-synergistic effect. So far, synergy mechanism of
probiotics and prebiotics has not been thoroughly understood;
hence, the extensive application of synbiotics has a long way
to go.
PLANT EXTRACTS
Plant materials are used widely in traditional systems of medicine
(Savoia, 2012). Plant extracts, also known as phytobiotics, have
been exploited in animal nutrition, particularly for their antimi-
crobial, anti-inﬂammatory, anti-oxidative, and anti-parasitic
activities (Vondruskova et al., 2010; Hashemi and Davoodi, 2011).
Many plants have beneﬁcial multifunctional properties derived
from their speciﬁc bioactive components. Biologically active con-
stituents of plants are mostly secondary metabolites, such as
terpenoids (mono- and sesquiterpenes, steroids, etc.), phenolics
(tannins), glycosides, and alkaloids (present as alcohols, alde-
hydes, ketones, esters, ethers, lactones, etc.; Huyghebaert et al.,
2011). Among 109 new antibacterial drugs, approved in the period
of 1981∼2006, 69% originated from natural products, and 21%
of the antifungal drugs were natural derivatives or compounds
mimicking natural products (Newman, 2008).
Plant extracts are generally considered safe and effective against
certain bacteria. They are extensively used in feed as growth
promoters and health protectants (Hashemi and Davoodi, 2011;
Abreu et al., 2012), particularly inAsian,African, and SouthAmer-
ican countries, and are gradually used in developed countries in
recent years. In pig production, it is thought that oregano, cinna-
mon, Mexican pepper, thyme, oregano, and Camellia sinensis can
decrease pathogenic microbial mass in the intestines (Manzanilla
et al., 2004; Namkung et al., 2004; Zanchi et al., 2008); sangrovit,
aged garlic extract, and allicin are able to increase body weight
gain (Borovan, 2004; Tatara et al., 2008); thyme, clove, oregano,
eugenol, and carvacrol are capable of improving pig performance
(Oetting et al., 2006; Costa et al., 2007). Effects of phytogenic
feed additives on the production performance of poultry are also
reported (Hashemi and Davoodi, 2010).
It is considered that plant extracts at minimum inhibitory
concentrations (MICs) of 100∼1000 μg/ml in the in vitro bac-
terial susceptibility tests possess antibacterial activities (Simoes
et al., 2009). Useful antimicrobial phytochemicals can be divided
into several categories, such as phenolics/polyphenols, ter-
penoids/essential oils, alkaloids, lectins/polypeptides (Windisch
et al., 2008). Phytochemicals exert their antimicrobial activity
through different mechanisms. For example, (1) tannins act by
iron deprivation and interactions with vital proteins such as
enzymes (Scalbert, 1991); (2) the main indoloquinoline alkaloid,
cryptolepine, is a DNA intercalator and an inhibitor of topoi-
somerase (Karou et al., 2006); and (3) saponins form complexes
with sterols presenting in the membrane of microorganisms,
causing membrane damages and consequent collapse of cells
(Morrissey and Osbourn, 1999). Essential oils have long been
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recognized for their antimicrobial properties (Lee et al., 2004),
but the exact antimicrobial mechanism is poorly understood.
In fact, the antimicrobial activities of many plant extracts have
not been elucidated clearly yet (Stavri et al., 2007). Some in vivo
observations support the assumption that the general antimicro-
bial potential of phytogenic feed additives is contributed to a
ﬁnal reduction of intestinal pathogen pressure (Windisch et al.,
2008). To the year of 2008, only two kinds of human-used
antibacterial plant extracts have completed the clinical trials, and
additional 13 plant extracts are under clinical trials (Harvey,
2008).
A common feature of phytobiotics is that they are a very com-
plex blend of bioactive components. There is a lot of variations
in the composition of phytobiotics due to the biological factors
(plant species, growing location, and harvest conditions), manu-
facturing (extraction/distillation and stabilization) and the storage
conditions (light, temperature, oxygen tension, and time; Huyghe-
baert et al., 2011). Only under certain circumstances, plant extracts
could improve animal performance and control diseases. Bird
growth responses to herbal plants are still controversial, since
the exact quality as well as the quantity of the active chemi-
cals in plant extract are required to determine the response for
bird performance (Cross et al., 2007), which are often lacking.
Some parameters that affect the efﬁcacy of the phytobioticsmainly
include the plant parts and their physical properties, the genetic
variation of the plant, age of the plant, different dosage used,
extraction method, harvest time, and compatibility with other
ingredients (Yang et al., 2009). In addition, the beneﬁcial effect of
dietary phytobiotics can be inﬂuenced by the nutritional status of
animals, the infection, the diet composition and the environment
condition (Giannenas et al., 2003).
It is difﬁcult to perform systematic and comprehensive toxi-
cology studies and safety assessment on herbs and their extracts,
due to their complex composition. The challenge is to identify and
quantify the multitude of actions in order to claim improving feed
utilization, animal physiology and health status. Currently, herbal
feed additives on the market do not meet the “trace and efﬁcient”
principle for feed additives. They are commonly used at very large
dose, generally at feed ratio of 1–2%, some up to 5%, and this
may affect the nutrition of a feed. Another consideration when
using phytogenic feed additives is the possible interactions with
other feed additives. There are reports on the adverse interactions
of phytogenics with enzyme preparations (Sarica et al., 2005) and
with protein throughpartial denaturation (Anadon et al., 2005). In
summary, although phytobiotics are a group of natural additives,
researches on their mechanisms of action, compatibility with diet,
toxicity and safety assessment need to be done before they can be
applied more extensively in animal feeds.
INHIBITORS TARGETING PATHOGENICITY
QUORUM SENSING INHIBITORS
Bacterial pathogenicity is, in part, under the regulation and control
of QS system (Swift et al., 2001). QS system consists of self-induced
signaling molecules (autoinducers, AIs), receptors, and down-
stream regulatory proteins. AIs are N-acyl homoserine lactones
(AHLs) secreted by Gram-negative bacteria, autoinducing peptide
(AIPs) secreted by Gram-positive bacteria, autoinducer-2 (AI-2),
and other signaling molecules such as quinolones, esters, and fatty
acids.
Inhibitors targeting QS can block the functions of QS system
and therefore prevent bacterial virulence regulated by QS system.
QS inhibitors (QSIs) are classiﬁed into three groups including
non-peptide small molecule, peptide (mainly AIPs homologs),
andproteinQSIs. Non-peptideQSIsmainly includeAHLs analogs,
such asACP homologs, L/D-S-adenosylhomocysteine and butyryl-
S-adenosyl-L-methionine (Parsek et al., 1999), which can interfere
with the synthesis of QS signal molecules or the binding to the
receptors. Mice treated with synthetic AIP-II had resistance to
S. aureus infection (Mayville et al., 1999) and treated with fura-
none observed the decrease of virulence of P. aeruginosa (Hentzer
et al., 2003). QS quenching enzymes and QS quenching anti-
bodies are proteinaceous QSIs (Amara et al., 2011). The former,
such as AHL-acylase, lactonase, oxidoreductases from Rhodococ-
cus and paraoxonase frommammals, degrade signalingmolecules.
Human and murine paraoxonases 1 show the host modulators
of P. aeruginosa QS (Ozer et al., 2005). In addition, competi-
tive organisms are able to clear the signal molecule to quench
QS (Kalia and Purohit, 2011). For instance, E. coli ingest AI-
2s to inﬂuence the QS of Vibrio harveyi (Xavier and Bassler,
2005). Bacteria with AHL-degrading activity protect Artemia spp.,
rotifers and larvae of turbot or prawn from infection (Nhan et al.,
2010). In animal serum, apolipoprotein B (ApoB) bind with AIP1
molecules of S. aureus, effectively reducing its QS (Peterson et al.,
2008).
Importance of QSIs is inferred from a growing number of
patents related to this ﬁeld in the last few years and extensive
researches in this ﬁeld (Kalia and Purohit, 2011; Romero et al.,
2012). QSI appears to be effective in vitro and in various ani-
mal models; however, all the structural classes of compounds that
have been studied and patented have limitations when used in vivo
(Bhardwaj et al., 2013):
(1) Except for LED209 that has entered pre-clinical trial, the vast
majority of QSIs cannot be widely applied because of their
toxicity to eukaryotic cells. Penicillic acid and patulin are toxic
to human cells, and halogenated furanone has carcinogenic
toxicity (Bjarnsholt and Givskov, 2007);
(2) Although QSI itself does not interfere with the growth of bac-
teria and thus dose not cause selective pressure on bacteria, it
is still possible for bacteria to develop new resistance (Kalia
and Purohit, 2011). For example, mutations of bacterial AHL
synthases and QS signal receptors (e.g., LuxR) remain (Kalia
and Purohit, 2011);
(3) Drugs based on AHL analogs could suffer from hydrolysis of
lactone ring and drugs based on proteins could have stability
problems. For example, lactonases produced in the human
airway epithelia show to quench QS signals from P. aerugi-
nosa (Chun et al., 2004). Therefore, special caution needs to
be exercised in the development of synthetic anti-QS analogs
based on the lactone core (Sintim et al., 2010). Unraveling the
structures of molecules like AI-3 and deciphering the struc-
tural nuances of AI-2 receptors, LuxS and the myriad signal
transduction cascades involved in QS processes are of utmost
importance;
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(4) Bacterium only use its speciﬁc signal molecules; therefore,
it is difﬁcult to ﬁnd a broad-spectrum QSIs (Bjarnsholt and
Givskov, 2008). Broad-spectrum QS quenching enzymes have
goodprospects, but thepossibility that proteinQSIsmay cause
host immune response should be considered;
(5) The degradation of QS signaling molecules will affect the
normal activities of the host intestinal ﬂora (Amara et al.,
2011);
(6) Expression of virulence factors in bioﬁlm-forming bacteria is
much lower than that in the planktonic bacteria (Resch et al.,
2005); hence, one has to consider the actual value to use QSIs
for treating pathogens which have generated bioﬁlms.
It is reported that bacteria are more sensitive to the antibiotics
when the antibiotics are used in combination with QSIs. There-
fore, combination usage serves a better strategy to enhance the
antimicrobial effects and prevent the bacterial resistance.
BIOFILM INHIBITORS
Bioﬁlms are structured consortium of bacteria embedded in a self-
produced polymer matrix consisting of polysaccharide, protein
and DNA. Bioﬁlm-forming bacteria may cause chronic infec-
tions because they show increased tolerance to antibiotics and
disinfectant chemicals as well as resisting phagocytosis and other
components of the body’s defense system (Hoiby et al., 2010). As
for treating staphylococcal bioﬁlm, protein synthesis inhibitors
(e.g., oxazolidinones and tetracyclines), cell membrane and
wall-active antibiotics (e.g., lipopeptides and glycopeptides) and
inhibitors for DNA and RNA synthesis (e.g., rifampin) are often
used (Kiedrowski andHorswill, 2011). Methane-thiosulfonate and
mercurial p-hydroxymercuribenzoic acid could target sortases,
a membrane enzyme catalyzing the covalent anchoring of sur-
face proteins to peptidoglycans, which are involved in bacteria
adhesion (Chen and Wen, 2011).
Bioﬁlm formation involves bacterial cell adhesion, QS reg-
ulation, bioﬁlm maturation, and bacteria spread; therefore, a
single drug is difﬁcult to completely remove pathogens in bioﬁlms.
Combination therapy is a wise choice, which generally uses antibi-
otics with antibiotics or antibiotics with bioﬁlm inhibitor as
the combination. Combination of both ﬂuoroquinolones and
macrolides or fosfomycin seems to be most effective regimen
against bioﬁlm infections in urinary tract (Kumon,2000). Another
promising strategy is the use of enzymes that can dissolve the
bioﬁlm matrix [e.g., polysaccharide hydrolases (Kaplan et al.,
2004), DNases (Izano et al., 2008), proteases (Marti et al., 2010),
and alginate lyases] as well as quorum-sensing inhibitors that
increase bioﬁlm susceptibility to antibiotics. It is shown that
administration of DNase and alginate lyase enhances the activ-
ity of tobramycin against bioﬁlms by dissolving the bioﬁlm
matrix of Pseudomonas aeruginosa (Alipour et al., 2009). In
addition, monoclonal antibody of alginate shows certain dam-
aging effects against P. aeruginosa bioﬁlms (Mai et al., 1993),
and enhances the ability of antibiotic to penetrate bioﬁlms
(Hatch and Schiller, 1998). Urokinase or lumbrokinase combin-
ing with ﬂeroxacin signiﬁcantly enhances the inhibition of P.
aeruginosa bioﬁlms (Selan et al., 1993). This combination not
only degrades the polysaccharide protein complex in the bac-
terial bioﬁlms, but also affects the bacterial DNA synthesis.
Efﬂux pump inhibitor in combination with miconazole can effec-
tively remove Candida albicans from the bioﬁlm (Qi and Wang,
2009).
The way from molecular mechanisms of bioﬁlm formation
to anti-bioﬁlm products is promising, but still a long one.
Although bioﬁlm inhibitors can inhibit bioﬁlm formation, they
do not inhibit bacterial growth or kill bacteria. Hence, when
bioﬁlm inhibitor use is discontinued, bacteria will produce bioﬁlm
again to protect themselves against the adverse environmental
conditions.
BACTERIAL VIRULENCE INHIBITORS
An important emerging strategy to combat bacteria seeks to block
the ability of bacteria to harm the host by inhibiting bacterial viru-
lence factors. Development of compounds inhibiting the function
and transmission of bacterial toxins is a novel anti-infective strat-
egy. The protein complex of anthrax toxin contains lethal factor
(LF), edema factor (EF),PA,andother components. Single compo-
nent is non-toxic, but the combinationof LForEFwithPAwill lead
to a pathological effect (Young and Collier, 2007). A small molecu-
lar, hydroxamate (LFI), can bind to the active site of LF, inhibiting
the activation of LF and preventing anthrax infection (Shoop et al.,
2005). Cisplatin shows inhibitory effect to PA heptamer assembly,
thus blocks the toxicity of LF and EF. However, only simultane-
ous feeding of cisplatin and a lethal amount of anthrax toxin has
a protective effect on rodents, while delayed feeding of cisplatin
would have resulted in a failure (Moayeri et al., 2006). Cholestyra-
mine can bind with clostridial toxin to prevent its adsorption to
intestinal epithelial cells, thus weakening the toxicity cause by the
toxin.
The type three secretion system (T3SS) is found in over two
dozens of Gram-negative bacteria and functions by injecting effec-
tor proteins directly into the cytosol of the host cells. One acyl
salicylaldehyde compound targeting the T3SS of Yersinia pseudo-
tuberculosis prevents the translocation of effector molecules, and
thus attenuates the pathogens (Nordfelth et al., 2005). Different
acyl salicylaldehydes inhibit two T3SS effector molecules to pre-
vent Salmonella invasion of the intestinal epithelial cells (Hudson
et al., 2007). Currently, studies on the acyl salicylaldehyde under
bovine intestinal model are still limited.
Prevention of bacterial adhesion is equally important. Pili-
cides inhibit bacterial pili formation. Pyridone and its N-terminal
amino acid derivatives competitively inhibit the chaperone pro-
tein binding to pilus protein. Pyridone is also able to inhibit blood
clotting and bioﬁlm formation, thus inhibiting bacterial adhesion
(Pinkner et al., 2006). Regulating the expression of bacterial viru-
lence factor is meaningful as well. For instance, virstatin inhibits
the expression of Vibrio cholerae toxin and pilus, thereby prohibit-
ing the colonization of V. cholerae in the gut (Hung et al., 2005).
Virulence regulation can be achieved through different aspects,
such as interfering bacterial QS (Clatworthy et al., 2007). Inhibi-
tion of the downstream effects of toxin is feasible. For example,
Cl− secretion inhibitors can moderate diarrhea.
Toxin inhibitors carry out the function by disrupting the bac-
terial toxins, or modulate the host responses to the toxins. They
do not directly inhibit bacteria, thus causing no bacteria resis-
tance selection pressure. However, like the bioﬁlm inhibitors, even
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in the presence of toxin inhibitors, bacteria can still grow and
reproduce. Therefore, in the absence of these substances, bacteria
may produce toxins and exhibit virulence again.
FEED ENZYMES
The nutrients for the multiplication and growth of bacteria in
the intestinal tract are derived largely from dietary components,
which are either not digested by digestive enzymes or absorbed
so slowly that bacteria in host guts compete for them. Exoge-
nous enzymes not only inﬂuence the absorption of nutrients
but also produce nutrients for speciﬁc populations of bacteria
through their action (Bedford and Cowieson, 2012). Therefore,
their use has a direct impact on the microﬂoral populations
(Apajalahti et al., 2004).
The most widely used feed enzymes are mixture of a variety
of glycanases, and the single-using degrading enzyme is phytase
(Ravindran and Son, 2011). Recombinant synthesized enzymes
such as phytases and carbohydrases are commercially produced
and sold as feed additives in monogastric food-animal production
(Adeola and Cowieson, 2011). Phytase has signiﬁcant effects on
the digestibility of calcium, phosphorus, and minerals as well as
the intestinal mucin production and the endogenous losses, all of
which inﬂuence the nutrient supply and the intestinal environ-
ment which will alter the selection pressures on bacterial species
(Bedford and Cowieson, 2012). Xylanase added to a wheat-based
diet alleviates the pathological effects of C. perfringens in broiler
chickens (Liu et al., 2012a). Dietary use of encapsulated lysozyme,
as a feed additive in the diet of chickens signiﬁcantly reduced the
concentration of C. perfringens and gastrointestinal lesions due to
the organism in the ilium (Liu et al., 2012b).
Despite themature phytasemarket, other kinds of feed enzymes
have different defects. Generally, the activity of the enzyme is low;
the cost is high; and the production and quality control lack stan-
dards. The stability and activity of feed enzymes depend mainly
on the production process (Slominski, 2011). It is well recognized
that animal responses to feed enzyme additives are not entirely
predictable, and these inconsistencies could be attributed inter
alia to the enzyme type, the amount of enzyme applied, the pres-
ence of enzyme side activities, the diet composition and the animal
variation (Ravindran and Son, 2011). The mechanisms by which
feed enzymes inﬂuence the intestinal microbiota have been known
for some time, e.g., through enhancing nutrient delivery to the
host and by provision of fermentable oligosaccharides. It is still
unknown, however, to which extent this effect contributes to the
net beneﬁt of the enzyme use, nor is it clear which are the major
microbial species involved (Bedford and Cowieson, 2012). Recent
work shows that if the use of enzymes is to replace prophylactic
antibiotics, then the target must be to enrich the ileum and cecum
with Clostridium cluster XIVa species and E. coli while depressing
the numbers of Lactobacillus spp. (Smulikowska et al., 2010). Until
an accurate description of a desirable ﬂora can be documented, the
feed enzymes can be appropriately used.
Since enzymes do not directly attack bacteria, but only reduce
the substrates for the growth of bacteria, the antibacterial effect
is not obvious. Glucose oxidase (GOD), mainly from Aspergillus
niger and Penicillium, can speciﬁcally oxidize D-glucose to pro-
duce gluconic acid and hydrogen peroxide (Geisen, 1999). When
hydrogen peroxide accumulates to a certain level, it can be harmful
to intestinal bacteria and inhibits their propagation while con-
suming oxygen in the intestine, which may help the growth of
Biﬁdobacterium and Lactobacillus and other beneﬁcial anaerobic
bacteria. An enzyme alginogel composed of GOD, lactoperoxi-
dase, and guaiacol was able to prevent the formation of bioﬁlms
and inhibit the established bioﬁlms (Cooper, 2013). Given that the
mechanism of action of this enzyme is different from other feed
enzymes, the related feeding effects of GOD are worthy of further
study.
PERSPECTIVES
Ideal alternatives to antibiotics should: (i) have non-toxic or no
side effects on animals, (ii) be easy to eliminate from the body
or consist of short term of residues, (iii) not induce bacterial
resistance, (iv) be stable in the feed and animal gastrointestinal
tract, (v) be easily decomposed and not affect the environment,
(vi) not affect palatability, (vii) not destroy the normal intestinal
ﬂora of animals, (viii) kill or inhibit the growth of pathogenic bac-
teria, (ix) enhance the body resistance to the disease, (x) improve
feed efﬁciency and promote animal growth, and (xi) have good
compatibility. In fact, there are no alternatives to antibiotic that
currently meet all the above mentioned requirements.
There is still a considerable gap between antibiotic alter-
natives and antibiotics concerning the effectiveness of disease
prevention and growth promotion. Antibacterial vaccines are
generally used for the prevention of bacterial infections, and cur-
rently only a small number of bacterial infective diseases can be
controlled by vaccines. Immunomodulators and feed enzymes
mainly preserve the health of animals, but do not directly kill
or inhibit bacteria. Bacteriophages are currently only used in
food, and the safety is still questionable. The composition of
plant extracts and probiotics is complex and the quality in terms
of stability is poor, resulting in varying effects and safety risks.
Inhibitors targeting QS and virulence of bacteria are still in
research with no approved products, and most QSIs are toxic
to eukaryotic cells. Bioﬁlm inhibitors show good results only
when used in combination with antibiotics. Although AMPs can
treat bacterial infections, the high cost and narrow antibacte-
rial spectrum restrict their wide use, and they can still induce
bacterial resistance. Meanwhile, proteinaceous compounds, for
example, feed enzymes and AMPs that have been put into
market as well as bacteriophage lysins, QS quenching enzymes
and enzymatic bioﬁlm inhibitors under development, are nat-
urally unstable and easily degraded in the digestive tract. On
the other hand, antibiotics can directly inhibit or kill bacteria
with better antibacterial effect than all antibiotic alternatives.
Moreover, antibiotics are made by single and relatively pure
active ingredient with high stability, consistency, and quality
ensured by good manufacturing practice. Considering clinical
efﬁcacy, humans have not yet found a more effective way than
selecting appropriate antibiotics for the treatment of indicated
bacteria.
Antimicrobial resistance is the major reason for EU to ban low
dose of antibiotics as feed additive. In fact, the penicillin’s pro-
ducer, Penicillium, has coexisted with other bacteria for tens of
thousands of years. Only after the extensive use of penicillin was
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the emergence penicillin-resistance discovered. Drug pressure is
proportional to the chance of development and dissemination of
drug resistance; therefore, although antibiotic alternatives have
not been associated with bacterial resistance yet, with a large num-
ber of these alternatives in use, bacteria might mutate eventually
to develop resistance. Like the precedent use of antibiotics, the
irregular and illegal use of antibiotic alternatives may also bring
negative issues.
Meanwhile, we must not forget that “it’s better to prevent than
cure” (Bourlioux, 2013). For many developing countries, because
of the poor farming environment and the high incidence of dis-
ease, antibiotics are still an effective tool in the prevention and
control of animal diseases. It is shown that the ban of growth
promoters in EU demands the improvement of the farm hygiene
(Castanon, 2007). When the amount of “old” antibiotics used in
feed reduces due to the ban, prevalence of bacterial infections
in the target animals would likely increase without fundamen-
tal improvement of production environment. This may lead to
the increase of therapeutic uses of advanced antibiotics and result
in some unintended consequence that may cause new challenges
for public health concern. Additionally, there are no scientiﬁc
evidences to clearly separate the causal relationship between treat-
ment use and prevention use of the antibiotics with respect to
resistance development. The ultimate beneﬁt and risk should be
assessed before implementing such a policy as a result of politi-
cal/social pressure, as bacteria may not necessarily “listen” to the
policy-makers. Thus, the decision concerning the use of in-feed
antibiotics should be made based on scientiﬁc approaches. The
ban of antibiotics as growth promoters cannot be copied in every
country of the world.
The efﬁcacy of traditional antibiotics can still be improved.
Some “old” antibiotics can ﬁnd new bacterial targets and rein-
force the anti-infectious therapy toward someMDRbacteria. It has
been demonstrated that in many cases, there are non-carbapenem
alternatives for the treatment of extended-spectrum-β-lactamase-
producing E. coli (ESBL-Ec) infections (Fournier et al., 2013).
Besides, new formulations can allow targeted drug delivery via
nanoparticles and the association of molecules can reinforce the
antimicrobial effect of antibiotics (Bourlioux,2013). Furthermore,
in empirical therapy, use of broad-spectrum bactericidal agents
that will eradicate the presumed infective microorganism(s),
which potentially could be MDR, should be preferred. Once
an infection is under control and the culture and susceptibility
results are reported, it is important to switch to the most suitable
narrow-spectrum agent thus decreasing the potential of adverse
drug effects and the risk of development of antibiotic-induced
resistance (Lynch, 2012).
In summary, reasonable use of antibiotics and continuous
development of alternatives to antibiotics are needed to ensure
the long-term sustainable development of animal husbandry. We
must strictly deﬁne the target animals, duration of the treatment
and the withdrawal period, for prudent use of antibiotics as well as
regulation/policymaking regarding their use. At the same time, we
must strengthen the supervision and enforcement of laws in order
to control antibiotic resistance and residues from the food chain
within established safe levels. Furthermore, we must improve the
management of animal nutrition and production hygiene, since
recent European developments showed a distinctly more positive
outcome of the ban of antibiotic growth promoters thanwas antic-
ipated during the ﬁrst years after the ban due to the improvement
of animal welfare (Cogliani et al., 2011). The research of antibi-
otics alternatives will be a long process. In addition to research
and development of new efﬁcient and safe alternatives, we should
strengthen the study concerning the effects of combined use of
antibiotics and their alternatives aimed at maintaining a healthy
agricultural economy and preservation of potent antibiotics for
efﬁcacious therapy in humans.
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